


USL311

Cat. No.:	HY-114244		
CAS No.:	1373268-67-7		
Molecular Formula:	C ₂₄ H ₃₄ N ₆ O		
Molecular Weight:	422.57		
Target:	CXCR		
Pathway:	GPCR/G Protein; Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 18.57 mg/mL (43.95 mM); ultrasonic and warming and heat to 80°C)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.3665 mL	11.8324 mL	23.6647 mL
	5 mM	0.4733 mL	2.3665 mL	4.7329 mL
	10 mM	0.2366 mL	1.1832 mL	2.3665 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (4.92 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (4.92 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (4.92 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

USL311 is a potent and selective CXCR4 antagonist, with anti-tumor activity. USL311 prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4^[1].

IC₅₀ & Target

CXCR4

REFERENCES

[1]. Takacs GP, et al. Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy. Pharmacol Ther. 2021 Jun;222:107790.

[2]. Peter Richardson. Usl-311 for use in the treatment of cancer. WO2018162924A1

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA